

FOR IMMEDIATE RELEASE

Contact: Sandra Richards,
Great Basin Scientific, Public Relations
801-201-8475

**GREAT BASIN SCIENTIFIC, INC. ANNOUNCES TWO NEW PATENT
FILINGS AFFECTING WHOLE-GENOME TESTING TECHNOLOGY**

*Leading Life Sciences Research Firm Progresses With Research and Development,
Intellectual Property Efforts*

LAS VEGAS, Nevada — December 1, 2005 — Great Basin Scientific today announced the filing of two patent applications related to enhanced sensitivity and capabilities of the company's thin-film biosensor test platform. The technologies covered by these patent filings represent significant steps in the Company's R&D efforts to develop a diagnostic test platform capable of whole genome testing without Polymerase Chain Reaction (PCR) and significantly strengthen the Company's patent portfolio

“While the strength and reliability of PCR is long proven, the process is expensive,” said David C. Ward, PhD, founder of Great Basin Scientific. “Once real efficiency and cost-effectiveness can be delivered in a test platform, the role of genetics in providing solid, practical answers to contemporary public health challenges will be matchless. Great Basin's long-term objective in intellectual property development to to move whole genome testing far beyond the limitations of traditional PCR, paving the way for unlimited molecular diagnostic and treatment potential.”

Ryan Ashton, CEO and president, Great Basin Scientific, concluded, “These patent filings serve as proof of progress towards the company's objective of delivering unique and improved whole genome testing technologies. Great Basin will continue to enhance patent portfolio value through additional filings and licensing, resulting in both a stronger competitive position for the company and increased innovation.”

About Great Basin Scientific

Founded in 2003 Great Basin Scientific, Inc. is dedicated to developing state-of-the-art technology and products that will improve automation, throughput, scalability and reliability of in-house rapid diagnostic testing for use by health care providers. GBS is based in Las Vegas, Nevada, with research laboratories in Nevada and Utah.

###